Summary
A bioRxiv preprint reports that bacteria sampled from chronic Pseudomonas aeruginosa lung infections in people with cystic fibrosis differed in susceptibility to some bacteriophages. The findings point to variation in bacterial cell-surface features as one possible reason and highlight a challenge for phage therapy.
A bioRxiv preprint reports that Pseudomonas aeruginosa bacteria sampled from chronic lung infections in people with cystic fibrosis can differ in their susceptibility to bacteriophages. The researchers tested 12 virulent phages against 40 bacterial isolates from each of four patient-derived populations. Susceptibility varied substantially for four phages that target lipopolysaccharide (LPS), a component of the bacterial cell surface, in two of the four populations.
Phages are viruses that infect bacteria, and many can attack only a subset of strains within a bacterial species. That specificity matters in a chronic infection: if bacterial variants within the same person respond differently, a phage active against one isolate may not work equally well against others. The study examines this variation in isolates from people with cystic fibrosis, rather than testing phage treatment in patients.
Cell-surface differences may help explain susceptibility
The researchers compared the isolates’ genomes and found that the presence of known phage-defence systems did not vary strongly within the lung-derived populations. This made differences in the carriage of those systems an unlikely explanation for the susceptibility patterns they observed.
A closer evolutionary analysis of isolates from one population found that some changes in phage susceptibility coincided with mutations in genes involved in LPS biosynthesis. Because LPS is part of the cell surface and the phages showing variation targeted LPS, the researchers suggest that differences in surface features may contribute to the pattern. The association does not by itself establish that those mutations caused the changes in susceptibility.
The study also examined bacterial traits related to antibiotic resistance. The authors reported a favorable association between phage susceptibility and antibiotic-resistance phenotypes in one population, but found that such associations were largely absent in the others. They therefore caution that using phages to drive favorable shifts in bacterial traits may be limited when infections already contain substantial variation.
The findings make within-infection diversity a practical consideration for phage selection: testing a single bacterial isolate may not capture how the wider population responds. This is isolate-level laboratory research reported as a preprint, not a clinical trial, so it identifies a potential treatment challenge rather than measuring whether phage therapy improves patient outcomes.